论文部分内容阅读
目的观察卡培他滨对综合治疗失败的复发转移性乳腺癌的疗效及毒副反应。方法36例病人按照希罗达+基础治疗的方案实施治疗。希罗达2500mg/(m2.d),每日2次餐后半小时口服、连服2周,休息1周,第4周重复上周期化疗。每2个周期评价1次疗效,病情进展停药。基础治疗包括营养支持治疗、癌痛治疗、贫血治疗、骨转移治疗等。结果全部病人均完成6个周期以上化疗。CR2例,PR15例,SD11例,PD8例,有效率47.2%,疾病控制率77.8%,中位无进展生存期8.2个月。1、2年生存率分别为66.7%、25%。主要的毒副反应为可逆性的手足综合征、皮肤色素沉着。结论对于综合治疗失败的复发转移性乳腺癌选择单药希罗达化疗仍是一个较好的治疗方案,患者的依从性、耐受性及安全性较好,值得临床推广应用。
Objective To observe the curative effect and side effects of capecitabine on the treatment of recurrent metastatic breast cancer. Methods Thirty-six patients were treated according to the Xeloda + basic treatment regimen. Xeloda 2500mg / (m2.d), 2 times a day orally for half an hour after meals, and even served 2 weeks, rest for 1 week, the first 4 weeks of repeat chemotherapy. Evaluation every 2 cycles of efficacy, the progression of the disease withdrawal. The basic treatment includes nutritional support treatment, cancer pain treatment, anemia treatment, bone metastasis treatment. Results All patients completed more than 6 cycles of chemotherapy. CR2 cases, PR15 cases, SD11 cases and PD8 cases, the effective rate was 47.2%, the disease control rate was 77.8%, and the median progression-free survival rate was 8.2 months. The 1-year and 2-year survival rates were 66.7% and 25% respectively. The main side effects are reversible hand-foot syndrome, skin pigmentation. Conclusions The single drug Xeloda chemotherapy is still a better treatment option for patients with recurrent metastatic breast cancer who failed in comprehensive treatment. The compliance, tolerability and safety of the treatment are good and worthy of clinical application.